Evidence map›Paper›PMID 35551471›Full record

ArticleActa neuropathologica2022

SCN1A overexpression, associated with a genomic region marked by a risk variant for a common epilepsy, raises seizure susceptibility.

Katri Silvennoinen, Kinga Gawel, Despina Tsortouktzidis, Julika Pitsch, Saud Alhusaini, Karen M J van Loo, Richard Picardo, Zuzanna Michalak, Susanna Pagni, Helena Martins Custodio and 16 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Dravet syndrome: novel insights intoFrontiers in neuroscience · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 10 institutions in 7 countries.

Katri Silvennoinen *Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, Box 29, Queen Square, London, WC1N 3BG, UK.ORCID https://orcid.org/0000-0001-8456-0029
Kinga Gawel *Chemical Neuroscience Group, Centre for Molecular Medicine Norway (NCMM), Faculty of Medicine, University of Oslo, 0349, Oslo, Norway.
Despina Tsortouktzidis *Institute of Neuropathology, Medical Faculty, University of Bonn, Section for Translational Epilepsy Research, 53127, Bonn, Germany.
Julika PitschInstitute of Neuropathology, Medical Faculty, University of Bonn, Section for Translational Epilepsy Research, 53127, Bonn, Germany.
Saud AlhusainiDepartment of Molecular and Cellular Therapeutics, The Royal College of Surgeons in Ireland, Dublin 2, Ireland.
Karen M J van LooInstitute of Neuropathology, Medical Faculty, University of Bonn, Section for Translational Epilepsy Research, 53127, Bonn, Germany.
Richard PicardoDepartment of Neuropathology, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
Zuzanna MichalakDepartment of Neuropathology, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
Susanna PagniDepartment of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, Box 29, Queen Square, London, WC1N 3BG, UK.
Helena Martins CustodioDepartment of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, Box 29, Queen Square, London, WC1N 3BG, UK.
James MillsDepartment of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, Box 29, Queen Square, London, WC1N 3BG, UK.
Christopher D WhelanDepartment of Molecular and Cellular Therapeutics, The Royal College of Surgeons in Ireland, Dublin 2, Ireland.
Greig I de ZubicaraySchool of Psychology, Faculty of Health, Queensland University of Technology (QUT), Brisbane, QLD, 4059, Australia.
Katie L McMahonSchool of Clinical Sciences, Faculty of Health, Queensland University of Technology (QUT), Brisbane, QLD, 4029, Australia.
Wietske van der EntChemical Neuroscience Group, Centre for Molecular Medicine Norway (NCMM), Faculty of Medicine, University of Oslo, 0349, Oslo, Norway.
Karolina J Kirstein-SmardzewskaChemical Neuroscience Group, Centre for Molecular Medicine Norway (NCMM), Faculty of Medicine, University of Oslo, 0349, Oslo, Norway.
Ettore TiraboschiChemical Neuroscience Group, Centre for Molecular Medicine Norway (NCMM), Faculty of Medicine, University of Oslo, 0349, Oslo, Norway.
Jonathan M MudgeEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, CB10 1SD, UK.
Adam FrankishEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, CB10 1SD, UK.
Maria ThomDepartment of Neuropathology, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
Margaret J WrightQueensland Brain Institute, University of Queensland, St Lucia, 4072 QLD, Australia.
Paul M ThompsonImaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, Los Angele, CA, 90292, USA.
Susanne SchochInstitute of Neuropathology, Medical Faculty, University of Bonn, Section for Translational Epilepsy Research, 53127, Bonn, Germany.
Albert J Becker *Institute of Neuropathology, Medical Faculty, University of Bonn, Section for Translational Epilepsy Research, 53127, Bonn, Germany.
Camila V Esguerra *Chemical Neuroscience Group, Centre for Molecular Medicine Norway (NCMM), Faculty of Medicine, University of Oslo, 0349, Oslo, Norway.
Sanjay M Sisodiya *Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, Box 29, Queen Square, London, WC1N 3BG, UK. s.sisodiya@ucl.ac.uk.
National Hospital for Neurology and Neurosurgery · GBUniversity of Bonn · DEUniversity of Oslo · NOEuropean Bioinformatics Institute · GBQueensland University of Technology · AUUniversity of Southern California · USMedical University of Lublin · PLQueen Mary University of London · GBRoyal College of Surgeons in Ireland · IEThe University of Queensland · AU

Funding

GENCODE Resource ProjectU41HG007234 · NHGRI · SANGER INSTITUTE · PI FLICEK, PAUL · 2013 to 2020
$20.3M
Department of HealthNHGRI NIH HHS U41 HG007234Wellcome TrustWellcome Trust WT104033AIAWellcome Trust WT108749/Z/15/ZWellcome Trust WT200990/Z/16/Z
6 · The paper itself

Abstract

Mesial temporal lobe epilepsy with hippocampal sclerosis and a history of febrile seizures is associated with common variation at rs7587026, located in the promoter region of SCN1A. We sought to explore possible underlying mechanisms. SCN1A expression was analysed in hippocampal biopsy specimens of individuals with mesial temporal lobe epilepsy with hippocampal sclerosis who underwent surgical treatment, and hippocampal neuronal cell loss was quantitatively assessed using immunohistochemistry. In healthy individuals, hippocampal volume was measured using MRI. Analyses were performed stratified by rs7587026 type. To study the functional consequences of increased SCN1A expression, we generated, using transposon-mediated bacterial artificial chromosome transgenesis, a zebrafish line expressing exogenous scn1a, and performed EEG analysis on larval optic tecta at 4 day post-fertilization. Finally, we used an in vitro promoter analysis to study whether the genetic motif containing rs7587026 influences promoter activity. Hippocampal SCN1A expression differed by rs7587026 genotype (Kruskal-Wallis test P = 0.004). Individuals homozygous for the minor allele showed significantly increased expression compared to those homozygous for the major allele (Dunn's test P = 0.003), and to heterozygotes (Dunn's test P = 0.035). No statistically significant differences in hippocampal neuronal cell loss were observed between the three genotypes. Among 597 healthy participants, individuals homozygous for the minor allele at rs7587026 displayed significantly reduced mean hippocampal volume compared to major allele homozygotes (Cohen's D = - 0.28, P = 0.02), and to heterozygotes (Cohen's D = - 0.36, P = 0.009). Compared to wild type, scn1lab-overexpressing zebrafish larvae exhibited more frequent spontaneous seizures [one-way ANOVA F(4,54) = 6.95 (P < 0.001)]. The number of EEG discharges correlated with the level of scn1lab overexpression [one-way ANOVA F(4,15) = 10.75 (P < 0.001]. Finally, we showed that a 50 bp promoter motif containing rs7587026 exerts a strong regulatory role on SCN1A expression, though we could not directly link this to rs7587026 itself. Our results develop the mechanistic link between rs7587026 and mesial temporal lobe epilepsy with hippocampal sclerosis and a history of febrile seizures. Furthermore, we propose that quantitative precision may be important when increasing SCN1A expression in current strategies aiming to treat seizures in conditions involving SCN1A haploinsufficiency, such as Dravet syndrome.

Indexed as

EpilepsyEpilepsy, Temporal LobeSeizures, FebrileAnimalsGenomicsGliosisHippocampusHumansNAV1.1 Voltage-Gated Sodium ChannelSclerosisZebrafishZebrafish ProteinsNAV1.1 Voltage-Gated Sodium ChannelSCN1A protein, humanscn1laa protein, zebrafishZebrafish ProteinsFebrile seizuresGenotypeHippocampal sclerosisMRIZebrafish

Identifiers

PMID35551471
PMCPMC9217876
OpenAlexW4280514603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.